YL-17424
KRAS Mutation Cancer
PreclinicalIND-enabling
Key Facts
About 280Bio
Developing oral RAS-targeted therapies for cancers driven by KRAS, NRAS, and HRAS mutations.
View full company profileKRAS Mutation Cancer
Developing oral RAS-targeted therapies for cancers driven by KRAS, NRAS, and HRAS mutations.
View full company profile